Flamma is hosting a CDMO Live event in Boston from October 20-21, 2026 at the Sheraton Copley Place.

Flamma is a global, trusted CDMO partner delivering chemistry driven excellence across the small molecule development and manufacturing spectrum. With more than seven decades of experience, Flamma supports programs from early stage process R&D through commercial production of APIs, registered starting materials, and advanced intermediates. The company is consistently recognized for CDMO leadership in areas such as Expertise, Reliability, Capabilities, Quality, Service, & Compatibility, reflecting its reputation as a high value partner capable of guiding complex projects to successful outcomes. Flamma operates an integrated global network that combines manufacturing excellence in Italy with strategic facilities in the United States and China. Its FDA inspected cGMP sites in Italy & a U.S. operation in Malvern, PA are strengthened by a fully owned & approved facility in Dalian, China, forming a resilient and scalable supply chain for innovator customers worldwide. The company continues to invest in its global infrastructure, including a new cGMP plant in Dalian which is part of a $200M expansion strategy designed to increase capacity, enhance technology, & reinforce long term supply security. In the U.S., Flamma USA provides early stage development capabilities, including high potency APIs & controlled substance handling, while leveraging parallel pathways with China operations to accelerate timelines & optimize costs. This interconnected model ensures speed, flexibility, & reliability across every stage of development. Flamma also advances collaboration & operational efficiency through digital modernization, implementing centralized electronic lab notebook systems to improve data visibility & coordination across its global sites. Driven by the principle “CDMO Excellence, Powered by Chemistry,” Flamma provides the scientific strength, global reach, and dependable partnership required to bring complex small molecule therapeutics from concept to commercial reality.